Maximizing the impact of the Cures Acceleration Network : : accelerating the development of new drugs and diagnostics : workshop summary / / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into c...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Washington, District of Columbia : : National Academies Press,, [2012] 2012 |
Year of Publication: | 2012 |
Language: | English |
Online Access: | |
Physical Description: | 1 online resource (131 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
5003379066 |
---|---|
ctrlnum |
(MiAaPQ)5003379066 (Au-PeEL)EBL3379066 (CaPaEBR)ebr10863714 (OCoLC)829421146 |
collection |
bib_alma |
record_format |
marc |
spelling |
Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation, issuing body. Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. Accelerating the development of new drugs and diagnostics Washington, District of Columbia : National Academies Press, [2012] 2012 1 online resource (131 pages) text rdacontent computer rdamedia online resource rdacarrier Includes bibliographical references (pages 71). Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN. Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description. Description based on print version record. Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries. United States. Institutes of Health. National Center for Advancing Translational Sciences. Cures Acceleration Network. Drug monitoring. Drug development United States. Drugs United States Design. Pharmaceutical industry United States Quality control. Electronic books. Olson, Steve, 1956- contributor. Claiborne, Anne B., contributor. National Institute of Medicine (U.S.). Board on Health Sciences Policy, issuing body. Print version: Institute of Medicine (U.S.). Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary. Washington, District of Columbia : National Academies Press, [2012] xvi, 115 pages ; 23 cm 9780309261166 (OCoLC)ocn811963294 (DLC)10863714 ProQuest (Firm) https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=3379066 Click to View |
language |
English |
format |
eBook |
author2 |
Olson, Steve, 1956- Claiborne, Anne B., National Institute of Medicine (U.S.). Board on Health Sciences Policy, |
author_facet |
Olson, Steve, 1956- Claiborne, Anne B., National Institute of Medicine (U.S.). Board on Health Sciences Policy, |
author2_variant |
s o so a b c ab abc |
author2_role |
TeilnehmendeR TeilnehmendeR TeilnehmendeR |
title |
Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / |
spellingShingle |
Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN. |
title_sub |
accelerating the development of new drugs and diagnostics : workshop summary / |
title_full |
Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
title_fullStr |
Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
title_full_unstemmed |
Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
title_auth |
Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / |
title_alt |
Accelerating the development of new drugs and diagnostics |
title_new |
Maximizing the impact of the Cures Acceleration Network : |
title_sort |
maximizing the impact of the cures acceleration network : accelerating the development of new drugs and diagnostics : workshop summary / |
publisher |
National Academies Press, |
publishDate |
2012 |
physical |
1 online resource (131 pages) |
contents |
Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN. |
isbn |
9780309261173 9780309261166 |
callnumber-first |
R - Medicine |
callnumber-subject |
RM - Therapeutics and Pharmacology |
callnumber-label |
RM302 |
callnumber-sort |
RM 3302 I58 42012 |
genre |
Electronic books. |
genre_facet |
Electronic books. |
geographic_facet |
United States. United States |
url |
https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=3379066 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
615 - Pharmacology & therapeutics |
dewey-full |
615.1/9 |
dewey-sort |
3615.1 19 |
dewey-raw |
615.1/9 |
dewey-search |
615.1/9 |
oclc_num |
829421146 |
work_keys_str_mv |
AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary AT olsonsteve maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary AT claiborneanneb maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary AT nationalinstituteofmedicineusboardonhealthsciencespolicy maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation acceleratingthedevelopmentofnewdrugsanddiagnostics AT olsonsteve acceleratingthedevelopmentofnewdrugsanddiagnostics AT claiborneanneb acceleratingthedevelopmentofnewdrugsanddiagnostics AT nationalinstituteofmedicineusboardonhealthsciencespolicy acceleratingthedevelopmentofnewdrugsanddiagnostics |
status_str |
n |
ids_txt_mv |
(MiAaPQ)5003379066 (Au-PeEL)EBL3379066 (CaPaEBR)ebr10863714 (OCoLC)829421146 |
is_hierarchy_title |
Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary / |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1792330867234832384 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04517nam a2200529 i 4500</leader><controlfield tag="001">5003379066</controlfield><controlfield tag="003">MiAaPQ</controlfield><controlfield tag="005">20200520144314.0</controlfield><controlfield tag="006">m o d | </controlfield><controlfield tag="007">cr cnu||||||||</controlfield><controlfield tag="008">130212t20122012dcu ob 100 0 eng|d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780309261166 (pbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0309261163 (pbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309261173</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(MiAaPQ)5003379066</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(Au-PeEL)EBL3379066</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CaPaEBR)ebr10863714</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)829421146</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">MiAaPQ</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">MiAaPQ</subfield><subfield code="d">MiAaPQ</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM302</subfield><subfield code="b">.I58 2012</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1/9</subfield><subfield code="2">23</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.).</subfield><subfield code="b">Forum on Drug Discovery, Development, and Translation,</subfield><subfield code="e">issuing body.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Maximizing the impact of the Cures Acceleration Network :</subfield><subfield code="b">accelerating the development of new drugs and diagnostics : workshop summary /</subfield><subfield code="c">Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.</subfield></datafield><datafield tag="246" ind1="3" ind2="0"><subfield code="a">Accelerating the development of new drugs and diagnostics</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, District of Columbia :</subfield><subfield code="b">National Academies Press,</subfield><subfield code="c">[2012]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (131 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (pages 71).</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record.</subfield></datafield><datafield tag="590" ind1=" " ind2=" "><subfield code="a">Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.</subfield></datafield><datafield tag="610" ind1="1" ind2="0"><subfield code="a">United States.</subfield><subfield code="b">Institutes of Health.</subfield><subfield code="b">National Center for Advancing Translational Sciences.</subfield><subfield code="b">Cures Acceleration Network.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug monitoring.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="z">United States</subfield><subfield code="x">Design.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States</subfield><subfield code="x">Quality control.</subfield></datafield><datafield tag="655" ind1=" " ind2="4"><subfield code="a">Electronic books.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olson, Steve,</subfield><subfield code="d">1956-</subfield><subfield code="e">contributor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Claiborne, Anne B.,</subfield><subfield code="e">contributor.</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">National Institute of Medicine (U.S.).</subfield><subfield code="b">Board on Health Sciences Policy,</subfield><subfield code="e">issuing body.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Institute of Medicine (U.S.).</subfield><subfield code="t">Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary.</subfield><subfield code="d">Washington, District of Columbia : National Academies Press, [2012]</subfield><subfield code="h">xvi, 115 pages ; 23 cm</subfield><subfield code="z">9780309261166</subfield><subfield code="w">(OCoLC)ocn811963294</subfield><subfield code="w">(DLC)10863714</subfield></datafield><datafield tag="797" ind1="2" ind2=" "><subfield code="a">ProQuest (Firm)</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=3379066</subfield><subfield code="z">Click to View</subfield></datafield></record></collection> |